Low‐dose activated factor IX complex concentrates (FEIBAR) for post‐operative haemostasis in a patient with high responding factor VIII inhibitors

A. BHAVE, A. SRIVASTAVA, V. LEE, A. J. DANIEL, D. DENNISON, G. D. SUNDERAJ, A. SUDARSANAM

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Replacement therapy in patients with severe haemophilia A is associated with the development of inhibitory antibodies in about 15% [1,2]. The presence of inhibitors of factor VIII greatly complicates and compromises the treatment of these patients because of the lack of any completely satisfactory product to treat them. Haemostatic management for surgery in patients with inhibitors is very difficult. A product frequently used to treat bleeding episodes in such patients is prothrombin complex concentrate (PCC) [3] or its activated derivative (APCC) [4]. Activated recombinant human factor VII is another option [5]. For both these modalities of treatment, there are no laboratory tests that can be used to monitor clinical efficacy [5, 6]. Porcine factor VII is therefore the preferred product for surgery in patients with high‐responding factor VIII inhibitors [7]. Unfortunately, none of these products are readily available in most developing countries, including India. We report the management of a patient with high‐responding factor VIII inhibitor using low doses of FEIBAR (Immuno, Austria) in the post‐operative period.

Original languageEnglish
Pages (from-to)274-276
Number of pages3
JournalHaemophilia
Volume1
Issue number4
DOIs
Publication statusPublished - 1995

Fingerprint

Factor IXa
Factor IX
Factor VIII
Hemostasis
Factor VII
Austria
Hemophilia A
Hemostatics
Postoperative Period
Developing Countries
prothrombin complex concentrates
India
Swine
Therapeutics
Hemorrhage
Antibodies

Keywords

  • factor IX complex concentrates
  • factor VIII inhibitors.
  • haemostasis
  • Keywords:

ASJC Scopus subject areas

  • Genetics(clinical)
  • Hematology

Cite this

Low‐dose activated factor IX complex concentrates (FEIBAR) for post‐operative haemostasis in a patient with high responding factor VIII inhibitors. / BHAVE, A.; SRIVASTAVA, A.; LEE, V.; DANIEL, A. J.; DENNISON, D.; SUNDERAJ, G. D.; SUDARSANAM, A.

In: Haemophilia, Vol. 1, No. 4, 1995, p. 274-276.

Research output: Contribution to journalArticle

BHAVE, A. ; SRIVASTAVA, A. ; LEE, V. ; DANIEL, A. J. ; DENNISON, D. ; SUNDERAJ, G. D. ; SUDARSANAM, A. / Low‐dose activated factor IX complex concentrates (FEIBAR) for post‐operative haemostasis in a patient with high responding factor VIII inhibitors. In: Haemophilia. 1995 ; Vol. 1, No. 4. pp. 274-276.
@article{b95423468b1c40ec9ba49ce3ae1c805a,
title = "Low‐dose activated factor IX complex concentrates (FEIBAR) for post‐operative haemostasis in a patient with high responding factor VIII inhibitors",
abstract = "Replacement therapy in patients with severe haemophilia A is associated with the development of inhibitory antibodies in about 15{\%} [1,2]. The presence of inhibitors of factor VIII greatly complicates and compromises the treatment of these patients because of the lack of any completely satisfactory product to treat them. Haemostatic management for surgery in patients with inhibitors is very difficult. A product frequently used to treat bleeding episodes in such patients is prothrombin complex concentrate (PCC) [3] or its activated derivative (APCC) [4]. Activated recombinant human factor VII is another option [5]. For both these modalities of treatment, there are no laboratory tests that can be used to monitor clinical efficacy [5, 6]. Porcine factor VII is therefore the preferred product for surgery in patients with high‐responding factor VIII inhibitors [7]. Unfortunately, none of these products are readily available in most developing countries, including India. We report the management of a patient with high‐responding factor VIII inhibitor using low doses of FEIBAR (Immuno, Austria) in the post‐operative period.",
keywords = "factor IX complex concentrates, factor VIII inhibitors., haemostasis, Keywords:",
author = "A. BHAVE and A. SRIVASTAVA and V. LEE and DANIEL, {A. J.} and D. DENNISON and SUNDERAJ, {G. D.} and A. SUDARSANAM",
year = "1995",
doi = "10.1111/j.1365-2516.1995.tb00089.x",
language = "English",
volume = "1",
pages = "274--276",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Low‐dose activated factor IX complex concentrates (FEIBAR) for post‐operative haemostasis in a patient with high responding factor VIII inhibitors

AU - BHAVE, A.

AU - SRIVASTAVA, A.

AU - LEE, V.

AU - DANIEL, A. J.

AU - DENNISON, D.

AU - SUNDERAJ, G. D.

AU - SUDARSANAM, A.

PY - 1995

Y1 - 1995

N2 - Replacement therapy in patients with severe haemophilia A is associated with the development of inhibitory antibodies in about 15% [1,2]. The presence of inhibitors of factor VIII greatly complicates and compromises the treatment of these patients because of the lack of any completely satisfactory product to treat them. Haemostatic management for surgery in patients with inhibitors is very difficult. A product frequently used to treat bleeding episodes in such patients is prothrombin complex concentrate (PCC) [3] or its activated derivative (APCC) [4]. Activated recombinant human factor VII is another option [5]. For both these modalities of treatment, there are no laboratory tests that can be used to monitor clinical efficacy [5, 6]. Porcine factor VII is therefore the preferred product for surgery in patients with high‐responding factor VIII inhibitors [7]. Unfortunately, none of these products are readily available in most developing countries, including India. We report the management of a patient with high‐responding factor VIII inhibitor using low doses of FEIBAR (Immuno, Austria) in the post‐operative period.

AB - Replacement therapy in patients with severe haemophilia A is associated with the development of inhibitory antibodies in about 15% [1,2]. The presence of inhibitors of factor VIII greatly complicates and compromises the treatment of these patients because of the lack of any completely satisfactory product to treat them. Haemostatic management for surgery in patients with inhibitors is very difficult. A product frequently used to treat bleeding episodes in such patients is prothrombin complex concentrate (PCC) [3] or its activated derivative (APCC) [4]. Activated recombinant human factor VII is another option [5]. For both these modalities of treatment, there are no laboratory tests that can be used to monitor clinical efficacy [5, 6]. Porcine factor VII is therefore the preferred product for surgery in patients with high‐responding factor VIII inhibitors [7]. Unfortunately, none of these products are readily available in most developing countries, including India. We report the management of a patient with high‐responding factor VIII inhibitor using low doses of FEIBAR (Immuno, Austria) in the post‐operative period.

KW - factor IX complex concentrates

KW - factor VIII inhibitors.

KW - haemostasis

KW - Keywords:

UR - http://www.scopus.com/inward/record.url?scp=84980299547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980299547&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.1995.tb00089.x

DO - 10.1111/j.1365-2516.1995.tb00089.x

M3 - Article

AN - SCOPUS:84980299547

VL - 1

SP - 274

EP - 276

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 4

ER -